OP Asset Management Ltd Takes $33.32 Million Position in Amgen Inc. $AMGN

OP Asset Management Ltd acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 94,708 shares of the medical research company’s stock, valued at approximately $33,323,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Anfield Capital Management LLC grew its stake in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the last quarter. Dogwood Wealth Management LLC raised its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen during the 4th quarter valued at $26,000. Manning & Napier Advisors LLC lifted its holdings in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new position in shares of Amgen in the fourth quarter worth approximately $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. UBS Group boosted their price target on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Guggenheim cut their target price on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Morgan Stanley lifted their price objective on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 9th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $354.42.

Amgen Price Performance

Shares of AMGN stock opened at $351.64 on Thursday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The stock has a fifty day simple moving average of $340.45 and a two-hundred day simple moving average of $345.95. The stock has a market capitalization of $189.78 billion, a price-to-earnings ratio of 24.47, a P/E/G ratio of 3.48 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.